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Obesity is associated with the impairment of endothelial function leading to the initiation of
the atherosclerotic process. As obesity is a multiple grade disease, we have hypothesized
that an increasing impairment of endothelial and vascular smooth muscle cell functions
occurs from lean subjects to severe obese ones, creating a window of opportunities for
preventive measures. Thus, the present study was carried out to investigate the grade
of obesity in which endothelial dysfunction can be detected and if there is an increasing
impairment of endothelial and vascular smooth muscle cell functions as body mass index
increases. According to body mass index, subjects were allocated into five groups: Lean
controls (n = 9); Overweight (n = 11); Obese class I (n = 26); Obese class II (n = 15);
Obese class III (n = 19). Endothelial and vascular smooth muscle cell functions were
evaluated measuring forearm blood flow responses to increasing intra-arterial infusions
of acetylcholine and sodium nitroprusside using venous occlusion plethysmography.
We observed that forearm blood flow was progressively impaired from lean controls to
severe obese and found no significant differences between Lean controls and Overweight
groups. Known determinants of endothelial dysfunction, such as inflammatory response,
insulin resistance, and diagnosis of metabolic syndrome, did not correlate with forearm
blood flow response to vasodilators. Moreover, several risk factors for atherosclerosis
were excluded as independent predictors after confounder-adjusted analysis. Our data
suggests that obesity per se could be sufficient to promote impairment of vascular
reactivity, that obesity class I is the first grade of obesity in which endothelial dysfunction
can be detected, and that body mass index positively correlates with the worsening of
endothelium-dependent and independent changes in forearm blood flow.
Keywords: obesity, overweight, endothelial function, vascular reactivity, venous occlusion plethysmography,
forearm blood flow
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Introduction
Obesity is the worldwide leading metabolic disease with
progressively increasing prevalence in developed and developing
countries. Due to the rising trend in its prevalence, by the year
2030, if no actions are taken against this threat, the number of
obese adults is projected to be around 600 million to 1 billion
individuals (Kelly et al., 2008). This alarming situation made the
World Health Organization refers to obesity as a global epidemic
(Formiguera and Cantón, 2004).
Besides being an important clinical and public health
burden in itself, obesity represents an important risk factor
for atherosclerosis-related cardiovascular diseases, such as
coronary artery disease. Indeed, some studies have indicated
that obesity is associated with the impairment of endothelial
function, one of the earliest markers of the atherosclerotic
process (Hashimoto et al., 1998; de Jongh et al., 2004;
Anderson, 2007; Yeboah et al., 2007). In this pathophysiological
model of atherosclerotic disease, before the development
of clinically overt atherosclerosis, arterial wall changes are
limited to impaired endothelial function (Hashimoto et al.,
2000).
As obesity is a multiple grade disease, we have hypothesized
that an increasing impairment of endothelial and vascular
smooth muscle cell functions occurs from lean subjects to
severe obese ones, creating a window of opportunities for
preventive measures. In fact, previous studies support the idea
of the existence of a reversible early stage of atherosclerosis
(Hashimoto et al., 2000). Unfortunately, although our current
knowledge offers a potential explanation for the relationship
between obesity and atherosclerosis, it still lacks the grade
of obesity in which endothelial dysfunction begins. Thus, the
present study was carried out to investigate the grade of obesity
in which endothelial dysfunction can be detected and if there
is an increasing impairment of endothelial and vascular smooth
muscle cell functions as body mass index increases. Additionally,
in order to perform a confounder-adjusted analysis we have tried
to correlate our findings with known determinants of endothelial
dysfunction, such as markers of inflammatory response, insulin
resistance, and diagnosis of metabolic syndrome.
Materials and Methods
Subjects
Eighty women, aged 18–30 years old, with sedentary lifestyle
were enrolled in this study. These subjects were consecutively
recruited from Rio de Janeiro State University’s outpatient
clinic and from community volunteers. A structured interview,
complete physical examination, and laboratory tests were
performed to exclude subjects with diseases other than
obesity, hypertension, hyperlipidemia, insulin resistance, and
metabolic syndrome. Patients with glucose intolerance, diabetes
Abbreviations: Ach, acetylcholine; BMI, body mass index; FBF, forearm blood
flow; HDL, high-density lipoprotein; HOMA-IR, Homeostasis Model Assessment-
Insulin resistance; IL-6, interleukin-6; LDL, low-density lipoprotein; NEFA, non-
esterified fatty acids; SNP, sodium nitroprusside.
mellitus, smoking habit, regular drinking habit, regular use
of medications, and clinical manifestations of atherosclerosis
were intentionally excluded due to known changes of vascular
function.
The Ethics Committee of Pedro Ernesto University Hospital
(Rio de Janeiro State University, Rio de Janeiro, Brazil) approved
the study design and protocol and, after receiving a thorough
explanation of the study, each subject gave written informed
consent before enrollment.
Study Design
Each subject made two visits (on two consecutive days) to the
Laboratory for Clinical and Experimental Research in Vascular
Biology at Rio de Janeiro State University. In the morning of the
first clinical visit, they were subjected to physical examination,
anthropometric measurements, and laboratory tests. Blood and
urine sampling was performed after 10–12 h overnight fast
to measure plasma glucose, lipid profile, insulin, and other
biochemical and inflammatory parameters. After fasting blood
sampling, all subjects underwent a 2-h 75-g oral anhydrous
glucose tolerance test to exclude glucose intolerance or diabetes
(according to American Diabetes Association criteria, American
Diabetes Association, 2014). In themorning of the second clinical
visit, venous occlusion plethysmography was performed after 8–
12 h overnight fast to assess endothelial function and vascular
reactivity.
Physical Examination, Anthropometric
Measurements, and Laboratory Tests
Arterial blood pressure was measured twice in supine
position with 5-min interval between measurements, using
an automated apparatus (LifeWindow LW6000, Digicare
Biomedical Technology, West Palm Beach, FL, USA). A
trained examiner collected all anthropometric measurements in
duplicate: waist was measured at its smallest point with a relaxed
abdomen, hip at the widest part of gluteal region, height using a
vertical bar stadiometer, and weight using a digital scale (Filizola,
São Paulo, SP, Brazil). Body mass index (BMI) was defined as the
ratio between weight in Kg and squared height in meters.
All laboratory measurements were performed in duplicate.
Plasma glucose level was assayed by the glucose oxidase method
and serum insulin level by electrochemiluminescence. Serum
non-esterified fatty acids (NEFA), serum total cholesterol, and
serum triglyceride levels were measured enzymatically. Serum
high-density lipoprotein (HDL) cholesterol level was measured
by the heparin-Ca2+/Ni2+ precipitation method. Serum C-
reactive protein was measured by immunoturbidimetry. Urinary
8-isoprostane, serum interleukin-6 (IL-6), serum leptin, serum
adiponectin, and serum resistin were assayed by ELISA. 8-
isoprostane was measured in urine due to methodological
problems with its serum measurement.
Low-density lipoprotein (LDL) cholesterol level was
calculated according to Friedwald equation. In order to
evaluate the insulin resistance status, the Homeostasis Model
Assessment (HOMA-IR) was calculated according to the
equation: HOMA-IR = [Plasma Glucose (in mmol/L) × Insulin
(in µUI/mL)/22.5], using fasting levels.
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Metabolic Syndrome Diagnosis
Metabolic syndrome was diagnosed according to NCEP-ATPIII
criteria (National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III), 2002),
which defines metabolic syndrome when three or more of the
following criteria are present: 1, waist circumference ≥88 cm;
2, triglycerides ≥150mg/dL; 3, HDL <50mg/dL; 4, fasting
plasma glucose concentration ≥100mg/dL; 5, arterial blood
pressure ≥130/85mmHg.
Venous Occlusion Plethysmography
Studies were carried out in a quiet temperature-controlled
room (21 ± 1◦C) with the subjects in supine position. Forearm
blood flow (FBF), in mL.100mL−1 forearm volume.min−1, was
measured by mercury-in-silastic strain gauge venous occlusion
plethysmograph (Hokanson EC6, D.E. Hokanson, Bellevue,
WA, USA) placed in the point of maximal circumference
of the non-dominant forearm, which was maintained at the
level of the heart. Drugs or normal saline were continuously
infused at 1.0mL.min−1 into the ipsilateral brachial artery
through a 27 SWG needle introduced under local anesthesia
(1mL of 1% lidocaine). After arterial needle insertion,
subjects were allowed to rest for 30min before any flow
measurement.
Endothelial and vascular smooth muscle cell functions, as
depicted by vascular reactivity, were evaluated measuring FBF
responses to intra-arterial infusion of three increasing doses
of endothelium-dependent [acetylcholine (Ach) 7.5, 15, and
30µg.min−1] and independent [sodium nitroprusside (SNP)
2, 4, 8µg.min−1] vasodilators, in this order. Each dose was
infused for 5min and FBF was recorded during the last 2min
of infusion. Prior to initiation of Ach and SNP, normal saline
was infused for 20min, and then blood flow measurements
were taken to establish resting control values (baseline).
This allowed an interval of 20min between Ach and SNP
infusions.
During the recording periods, hand circulation was excluded
by inflating a wrist cuff to suprasystolic pressure 1min before
flow measurement. The upper arm congesting cuffs were
intermittently inflated to 40mmHg for 10 s in 15 s cycles
to temporally occlude venous return, producing five flow
measurements (slopes). Venous occlusion plethysmography
apparatus was connected to an analog-to-digital converter
(PowerLab 8/35, AD Instruments, Castle Hill, Australia) and
data were recorded directly onto computer for later analysis with
LabChart Pro 8 software (AD Instruments, Castle Hill, Australia).
The first flow measurement was always excluded and the mean
of the remaining four measurements in each recording period
was used for data analysis. Responses to each dose of Ach or SNP
were summed and analyzed as Cumulative FBF, which represents
an integrated measurement of the cumulative response to the
progressive doses of each vasodilator.
During FBF measurement, arterial blood pressure was
measured in contralateral arm using a semiautomated
oscillometric device (LifeWindow LW6000, Digicare Biomedical
Technology, West Palm Beach, FL, USA).
Statistical Analysis
Results are expressed as means ± standard deviation of the
mean (SD) for each group, unless otherwise noted. Statistical
comparisons of normally distributed variables were performed
using One-Way ANOVA, whereas Kruskal-Wallis test was
used for other variables. When appropriate, an adequate test
was used for post-hoc analysis: Bonferroni method or Dunn’s
multiple-comparisons. We also have performed univariate and
multiple regression analysis of cumulative FBF responses to
intra-arterial infusion of vasodilators in relation to other
study variables or set of variables in order to find significant
correlations and to perform confounder-adjusted analysis.
Spearman correlation coefficients and p-values were calculated
for univariate analysis. All statistical analyses were performed
using Stata 10.1 (StataCorp, College Station, TX, USA) and
GraphPad Prism 6.03 (GraphPad Software, La Jolla, CA, USA)
and the significance level was set as p < 0.05 for a two-tailed test.
Results
According to BMI, subjects were allocated into five groups for
data analysis: 1, Lean controls (n = 9; BMI= 22.2± 1.3 kg.m−2);
2, Overweight (n = 11; BMI = 27.5 ± 1.4 kg.m−2); 3, Obese
class I (n = 26; BMI = 32.3 ± 1.4 kg.m−2); 4, Obese class II
(n = 15; BMI = 37.6 ± 1.6 kg.m−2); 5, Obese class III (n =
19; BMI = 44.0 ± 2.4 kg.m−2). Clinical, anthropometric, and
laboratory characteristics of groups are presented in Table 1.
When compared with lean subjects, obese class I, II, and
III ones showed greater systolic blood pressure, serum insulin
levels, HOMA-IR, and leptin levels but lower HDL-cholesterol
and adiponectin levels. IL-6 was significantly greater in Obese
class II and III groups. Obese class III group had a significantly
greater percentage of subjects with metabolic syndrome.
Venous Occlusion Plethysmography
Baseline FBF did not significantly differ between groups
(Table 2). Ach and SNP intra-arterial infusions were associated
with FBF improvements in all groups, but when compared with
lean subjects, significant impairment of vascular reactivity was
observed in obese class I, II, and III ones (Table 2). A lesser
cumulative FBF response to intra-arterial infusion of Ach was
observed in obese class I, II, and III subjects when compared with
lean and overweight ones (Figure 1A). However, no significant
differences were found between lean, overweight, obese class
I, and obese class II subjects when cumulative FBF response
to intra-arterial infusion of SNP was analyzed (Figure 1B).
Comparisons between the three obese groups showed greater
impairment of vascular reactivity in obese class III subjects
(Table 2 and Figure 1). No significant differences were found
between Lean controls and Overweight groups.
On univariate analysis BMI (r = −0.69; p < 0.0001), systolic
blood pressure (r = −0.25; p = 0.03), waist circumference
(r = −0.58; p < 0.0001), hip circumference (r = −0.64; p <
0.0001), leptin levels (r = −0.54; p < 0.0001), and adiponectin
levels (r = 0.47; p = 0.0001) showed significant correlation with
the cumulative FBF responses to intra-arterial infusion of Ach,
whereas BMI (r = −0.54; p < 0.0001), systolic blood pressure
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TABLE 1 | Clinical, anthropometric, and laboratory characteristics of groups.
Lean controls Overweight Obese class I Obese class II Obese class III
Age (years) 22.7± 3.3 26.2±3.2 25.0± 3.2 25.5±3.4 25.9±3.1
Weight (kg) 55.4± 5.5# 73.5±5.3# 83.0± 9.1# 96.0±10.0# 113.9±13.2#
Waist (cm) 66.8± 4.6# 85.9±6.6# 95.2± 8.1# 102.1±8.3# 111.9±9.5#
Hip (cm) 94.7± 6.9 104.6±6.9 112.5± 6.0* 122.0±7.6* 132.6±10.5*
Systolic blood pressure (mmHg) 108.9± 9.0 118.8±13.7 128.3± 10.8* 129.1±12.4* 133.0±15.8*
Diastolic blood pressure (mmHg) 68.7± 10.1 76.2±10.9 76.1± 8.6 76.3±6.5 77.1±10.2
Fasting plasma glucose (mmol.L−1 ) 4.6± 0.2 4.8±0.2 4.9± 0.2 4.8±0.2 4.9±0.1
Serum insulin (µUI.mL−1 ) 5.7± 2.7 11.5±5.6 15.5± 8.3* 20.3±10.5* 22.3±10.4*
HOMA-IR 1.2± 0.5 2.6±1.2 3.4± 2.0* 4.5±2.5* 4.8±2.3*
Serum total cholesterol (mg.dL−1) 180.9± 22.9 174.3±34.6 196.5± 27.4 168.3±22.6 184.1±35.0
LDL-cholesterol (mg.dL−1) 95.2± 23.6 99.7±29.1 116.3± 26.4 97.3±17.7 110.8±30.5
Serum HDL-cholesterol (mg.dL−1) 67.9± 12.9 52.2±13.1 53.3± 14.4 48.7±10.5* 46.7±13.3*
Serum triglycerides (mg.dL−1) 74.0± 25.0 92.5±30.2 134.3± 72.6 111.5±52.1 132.6±67.5
Serum leptin (pg.mL−1) 11,163± 5217 23,086±6190 35,266± 20,105* 53,534±17,602* 49,847±23,798*
Serum adiponectin (ng.mL−1 ) 13,205± 2660 7965±6996 5789± 2154* 4401±1848* 5275±2339*
Serum resistin (ng.mL−1) 8.5± 3.1 7.5±2.6 7.0± 2.9 7.9±3.8 8.4±5.8
Serum NEFA (mmol.L−1 ) 0.4± 0.2 0.7±0.1 0.7± 0.3 0.8±0.2* 0.7±0.2
Serum C-reactive protein (mg.dL−1) 0.4± 0.3 0.4±0.3 0.9± 0.7 1.0±0.7 0.7±0.5
Serum IL-6 (pg.mL−1) 1.4± 0.2 2.0±0.9 1.9± 0.8 3.6±2.4* 2.9±1.2*
Urinary 8-isoprostane (pg/µmol creatinine) 77.6± 18.7 106.6±65.6 114.7± 103.4 131.7±107.8 148.0±145.6
Percentage of subjects with metabolic syndrome diagnosis (%) 0% 0% 42% 27% 63%*
Results are expressed as means ± SD for each group. *p < 0.05 as compared with Lean controls group. #p < 0.05 as compared with any other group.
TABLE 2 | Forearm blood flow (FBF) at baseline and after all three doses of Ach or SNP.
Lean controls Overweight Obese class I Obese class II Obese class III
FBF prior to Ach infusion 1.5±0.4 1.7± 0.4 2.1±0.6 1.9± 0.5 1.7±0.5
FBF after Ach infusion 10.9±2.9 9.4± 3.0 6.6±1.5* 5.9± 1.5* 3.7±1.1#
FBF prior to SNP infusion 1.6±0.6 1.9± 0.2 2.1±0.7 1.8± 0.7 2.0±0.7
FBF after SNP infusion 9.6±1.8 9.3± 1.6 7.6±2.2* 6.7± 1.9* 5.1±1.5#
Results are expressed as means ± SD for each group. FBF is expressed in mL.100mL−1 forearm volume.min−1. *p < 0.05 as compared with Lean controls group. #p < 0.05 as
compared with any other group.
(r = −0.35; p = 0.002), waist circumference (r = −0.41; p =
0.0002), hip circumference (r = −0.51; p < 0.0001), and leptin
levels (r=−0.53; p < 0.0001) showed significant correlationwith
the cumulative FBF responses to intra-arterial infusion of SNP.
After confounder-adjustment, on multiple regression analysis
only BMI showed significant correlation with the cumulative FBF
responses to intra-arterial infusion of vasodilators (R2 = 0.47
for Ach and 0.28 for SNP). Spearman correlation coefficients for
univariate analysis of BMI data are presented in Figure 2.
Arterial blood pressure level evolution during vasodilators
infusions showed no systemic effects of drugs nor significant
differences between groups (data not shown).
Discussion
This study showed that vascular reactivity to intra-arterial
infusions of endothelium-dependent (Ach) and independent
(SNP) vasodilators, was greater in lean subjects than in
obese ones. Several studies have already indicated that obesity
is associated with the impairment of endothelial function
(Hashimoto et al., 1998; de Jongh et al., 2004; Anderson,
2007; Yeboah et al., 2007), and that an inflammatory state
associated with the release of a variety of cytokines and
cytokine-like substances, such as leptin and resistin, is among
the mechanisms that underlie the resultant microvascular
dysfunction (Singer and Granger, 2007). An altered sympathetic
neuronal responsiveness leading to diminished nitric-oxide
dilation has also been suggested (Vollenweider et al., 1994). Our
new finding was that an increasing impairment of endothelium-
dependent and independent changes in FBF could be observed
as BMI increases. Statistically, not only univariate analysis but
also multiple regression analysis confirmed that BMI is an
independent variable relating to cumulative FBF response to
vasodilators.
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FIGURE 1 | Cumulative forearm blood flow (FBF) after intra-arterial infusions of Ach or SNP. (A,B) Show the cumulative FBFs derived from the sum of
responses to each dose of Ach or SNP. †p < 0.05 as compared with Lean controls or Overweight groups. **p < 0.05 as compared with Obese class I group.
FIGURE 2 | Scatter plots of significant correlations between
cumulative forearm blood flow (FBF) responses to intra-arterial
infusion of vasodilators and body mass index (BMI). (A,B) Note that the
less the BMI is, the better the cumulative response to the progressive doses
of vasodilators are. Spearman correlation coefficient and p-values for
univariate analysis are shown for each correlation. n = 80.
Other important finding of our study was that no statistical
differences were observed in vascular smooth muscle cell
function between lean, overweight, obese class I, and obese class
II subjects (considering cumulative SNP response data) and in
both endothelial and smooth muscle cell function between lean
subjects and overweight ones. Together, these findings support
the hypotheses that obesity class I is the first grade of obesity
in which endothelial dysfunction can be detected, that arterial
wall damages progress in direct relationship with BMI, and
that in initial stages of obesity (obesity class I and II) before
the development of overt atherosclerosis with vascular smooth
muscle cell function impairment, arterial wall changes are limited
to impaired endothelial function. Of note, it has already been
shown that implementation of strategies targeting the reduction
of risk factors related to atherosclerotic disease resulted in
improvements of impaired endothelial function (Celermajer
et al., 1993; Vogel, 1999; de Kleijn et al., 2001; Gokce et al.,
2002; Taddei et al., 2002), allowing us to hypothesize about the
existence of a “potentially reversible stage of atherosclerosis”
when preventive measures could be taken. Unfortunately, despite
considerable amount of evidence that impaired endothelial
function can be improved by risk reduction strategies, no
consensus exists that the reversal of endothelial dysfunction is
associated with a reduction in cardiovascular events (Taddei et al.,
2002).
Interestingly, known determinants of endothelial dysfunction,
such as inflammatory response, insulin resistance (using HOMA-
IR as a surrogate marker), and diagnosis of metabolic syndrome,
did not correlate with FBF response to vasodilators in our study.
Moreover, several risk factors for atherosclerosis were excluded
as independent predictors after confounder-adjusted analysis.
Our results indicated that obesity per se could be sufficient to
promote impairment of endothelial function and vascular wall
reactivity. The selection of young subjects and exclusion of those
with diabetes mellitus, smoking habit, regular use of medications,
and clinical manifestations of atherosclerosis, imposing age and
disease restrictions to our study design may have helped in
dealing with confounding variables, clarifying the role of obesity.
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Finally, we have chosen to measure FBF with venous
occlusion plethysmography method given its minimally invasive
characteristic and our previous experience with this methodology
(de Aguiar et al., 2006). Furthermore, systemic administration
of vasoactive drugs may lead to central effects, hormonal
responses, changes in sympathetic output, and alterations in
blood pressure that make changes in forearm blood flow difficult
to interpret (Benjamin et al., 1995). Thus, another advantage of
our in vivo study model is the possibility to elevate flow locally
by intra-arterial infusions of sub-systemic doses of vasodilators
(often 100–1000 times lower than a systemically effective dose),
obviating any confounding systemic effects on drug response.
Drugs are infused through a fine needle placed in the brachial
artery allowing the study of the direct vascular effects, without
affecting systemic parameters. There is extensive worldwide
experience with this technique and it is considered quite safe
(Benjamin et al., 1995).
In conclusion, the present study demonstrated that obesity
class I is the first grade of obesity in which endothelial
dysfunction can be detected, that BMI is an independent
variable relating to FBF response to intra-arterial infusions of
vasodilators, existing an increasing impairment of such response
when BMI increases, and that the worsening of vascular response
to vasodilators is limited to an impaired endothelium-dependent
response in initial stages of obesity.
Limitations and Perspectives
Our study has some limitations. First, fitting BMI as a predictor
in our linear model resulted in low R-squared coefficients,
allowing us to hypothesize that other non-measured/studied
predictors are present. Those predictors could help to explain
part of the variations in vascular reactivity to intra-arterial
infusions of vasodilators fitting better linear models. Second,
the observational design of our study does not allow further
inferences about the reversal of endothelial dysfunction with
implementation of preventive measures. Third, although our
inclusion/exclusion criteria may have helped in dealing with
confounding, it may have decreased the external validity of our
findings. Finally, we cannot exclude that the relatively small
and unbalanced number of subjects per group may have biased
our findings. Further studies are needed to elucidate these
issues.
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